RhumbLine Advisers
PRLD icon

RhumbLine Advisers’s Prelude Therapeutics PRLD Stock Holding History

RhumbLine Advisers’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,499
Closed -$11.9K – 4231
2025
Q1 		$11.9K Sell
15,499
-151,331
-91% -$141K ﹤0.01% 3807
2024
Q4 		$213K Buy
166,830
+154,826
+1,290% +$205K ﹤0.01% 3165
2024
Q3 		$24.8K Sell
12,004
-9,561
-44% -$44.3K ﹤0.01% 3794
2024
Q2 		$82.2K Buy
21,565
+399
+2% +$1.62K ﹤0.01% 3567
2024
Q1 		$100K Buy
21,166
+763
+4% +$2.97K ﹤0.01% 3447
2023
Q4 		$87.1K Sell
20,403
-13,412
-40% -$40.8K ﹤0.01% 3494
2023
Q3 		$104K Buy
33,815
+3,996
+13% +$15K ﹤0.01% 3447
2023
Q2 		$134K Buy
+29,819
New +$178K ﹤0.01% 3415
2022
Q2 		– Sell
-10,050
Closed -$69K – 3205
2022
Q1 		$69K Buy
+10,050
New +$91.9K ﹤0.01% 2948
2021
Q4 		– Sell
-9,275
Closed -$290K – 3020
2021
Q3 		$290K Buy
9,275
+500
+6% +$16.2K ﹤0.01% 2779
2021
Q2 		$251K Sell
8,775
-886
-9% -$31.5K ﹤0.01% 2858
2021
Q1 		$419K Buy
9,661
+115
+1% +$7.63K ﹤0.01% 2569
2020
Q4 		$683K Buy
+9,546
New +$475K ﹤0.01% 2311

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

RhumbLine Advisers's PRLD Position: Q2 2025 in Review

RhumbLine Advisers sold out of Prelude Therapeutics (PRLD) in Q2 2025, closing a stake of 15,499 shares — an estimated $11.9K sold.

RhumbLine Advisers first reported a position in PRLD in Q4 2020 and held it in 13 quarters. The position peaked at $683K in Q4 2020. 50 funds tracked by Wall St. Rank hold PRLD as of Q2 2025.

  • RhumbLine Advisers reported no remaining Prelude Therapeutics position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 15,499 Prelude Therapeutics shares in Q2 2025, an estimated $11.9K.
  • RhumbLine Advisers first reported a position in Prelude Therapeutics in Q4 2020 and held it in 13 quarters.
  • RhumbLine Advisers's Prelude Therapeutics position peaked at $683K in Q4 2020.
  • 50 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.